Search Medical Condition
Please enter condition
Please choose location

Pescara, Italy Clinical Trials

A listing of Pescara, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (30) clinical trials

Observational Controlled Clinical Trials on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical Anatomy -Pathological Parameters

Observational prospective Clinical Trial designed to: - record all patients treated with a latest generation ALL-like therapy (e.g.: Holzer, LSA2-L2 modified, GIMEMA LAL094), an enhanced therapy (hyper-CVAD or Stanford), autologous or allogeneic transplant or reduced intensity conditioning allotransplant after induction/consolidation and also expected cases treated with high dose sequential therapy ...

Phase N/A

0.0 miles

Learn More »

Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.

The incidence of delayed thrombocytopenia in patients who undergo allogeneic hemopoietic stem cell transplant (SCT) is nearly 20-40% (1-2). Chronic graft versus host disease (cGVHD) seems to be the most frequent pathologic condition associated with post SCT delayed thrombocytopenia. Previous studies indicated the occurrence of delayed thrombocytopenia as a poor ...

Phase

0.0 miles

Learn More »

Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

OBJECTIVES: - Compare the feasibility, toxicity, and antileukemic activity of two different dosing regimens of gemtuzumab ozogamicin (GO) vs standard supportive care in older patients with previously untreated acute myeloid leukemia who are not candidates for intensive chemotherapy. (phase II) - Compare the efficacy and toxicity of the best dosing ...

Phase

0.57 miles

Learn More »

Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses

This is a multi-center, randomized, phase 2 trial to characterize the safety and efficacy of ponatinib over a range of 3 starting doses. Eligible patients must have chronic phase chronic myeloid leukemia (CP-CML) and be resistant to at least 2 tyrosine kinase inhibitors (TKIs).

Phase

1.05 miles

Learn More »